Bio-Reference Laboratories Company Profile (NASDAQ:BRLI)

About Bio-Reference Laboratories (NASDAQ:BRLI)

Bio-Reference Laboratories logoBio-Reference Laboratories, Inc. is a clinical testing laboratory, which offers testing, information and related services to physician offices, clinics, hospitals, employers and governmental units. The Company offers a range of laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring and treatment of diseases. It is focused on esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional health care. It offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology and other tissue analysis. It operates a clinical knowledge management service through its PSIMedica business unit. It also operates a Web-based connectivity portal solution for laboratories and physicians through its CareEvolve subsidiary. Its laboratory testing business consists of routine testing and esoteric testing.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical & Diagnostic Laboratories
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:BRLI
  • CUSIP: 09057G60
  • Web: www.bioreference.com
Average Prices:
  • 50 Day Moving Avg: $41.81
  • 200 Day Moving Avg: $36.97
  • 52 Week Range: $26.32 - $47.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.98
  • P/E Growth: 0.00
Profitability:
  • Net Margins: 4.67%
  • Return on Equity: 12.67%
  • Return on Assets: 8.38%
Misc:
  • Average Volume: 653,202 shs.
 

Frequently Asked Questions for Bio-Reference Laboratories (NASDAQ:BRLI)

What is Bio-Reference Laboratories' stock symbol?

Bio-Reference Laboratories trades on the NASDAQ under the ticker symbol "BRLI."

How were Bio-Reference Laboratories' earnings last quarter?

Bio-Reference Laboratories Inc (NASDAQ:BRLI) posted its quarterly earnings data on Thursday, December, 18th. The company reported $0.66 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.63 by $0.03. The firm earned $227.60 million during the quarter, compared to the consensus estimate of $228.81 million. Bio-Reference Laboratories had a return on equity of 12.67% and a net margin of 4.67%. The firm's revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.40 EPS. View Bio-Reference Laboratories' Earnings History.

Who are some of Bio-Reference Laboratories' key competitors?

How do I buy Bio-Reference Laboratories stock?

Shares of Bio-Reference Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Reference Laboratories' stock price today?

One share of Bio-Reference Laboratories stock can currently be purchased for approximately $34.61.


MarketBeat Community Rating for Bio-Reference Laboratories (NASDAQ BRLI)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Bio-Reference Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio-Reference Laboratories (NASDAQ:BRLI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Bio-Reference Laboratories (NASDAQ:BRLI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Bio-Reference Laboratories (NASDAQ:BRLI)
Earnings by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
Earnings History by Quarter for Bio-Reference Laboratories (NASDAQ BRLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/8/2015Q215$0.46$0.38$227.33 million$224.00 millionViewListenView Earnings Details
3/5/2015Q115$0.36$0.24$216.40 million$209.00 millionViewListenView Earnings Details
12/18/2014Q414$0.63$0.66$228.81 million$227.60 millionViewListenView Earnings Details
8/27/2014Q314$0.53$0.55$210.44 million$222.10 millionViewListenView Earnings Details
6/5/2014Q214$0.32$0.37$0.20 million$201.30 millionViewListenView Earnings Details
3/4/2014Q114$0.14$0.11$175.52 million$181.30 millionViewListenView Earnings Details
12/19/2013Q4$0.40$0.40$188.96 million$192.20 millionViewListenView Earnings Details
8/29/2013Q3 2013$0.51$0.53$183.50 million$185.40 millionViewListenView Earnings Details
6/6/2013Q2 2013$0.41$0.41$176.04 million$176.50 millionViewListenView Earnings Details
2/28/2013Q1 2013$0.28$0.31$165.44 million$161.30 millionViewListenView Earnings Details
12/6/20120.46$0.46$175.46 millionViewListenView Earnings Details
8/30/2012Q312$0.43$0.45$0.17 million$0.17 millionViewN/AView Earnings Details
6/7/2012$0.32$0.33ViewN/AView Earnings Details
3/1/2012$0.21$0.26ViewN/AView Earnings Details
12/8/2011$0.35$0.37ViewN/AView Earnings Details
8/25/2011$0.34$0.36ViewN/AView Earnings Details
5/26/2011$0.24$0.26ViewN/AView Earnings Details
3/3/2011$0.17$0.28ViewN/AView Earnings Details
12/16/2010$0.30$0.31$124.19 million$126.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Reference Laboratories (NASDAQ:BRLI)
Current Year EPS Consensus Estimate: $1.98 EPS
Next Year EPS Consensus Estimate: $2.31 EPS

Dividends

Dividend History for Bio-Reference Laboratories (NASDAQ:BRLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Reference Laboratories (NASDAQ:BRLI)
Insider Trades by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
Insider Trades by Quarter for Bio-Reference Laboratories (NASDAQ:BRLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2013Howard DubinettCOOSell20,000$29.40$588,000.00View SEC Filing  
6/27/2013Sam SingerCFOSell4,000$28.95$115,800.00View SEC Filing  
6/26/2013Sam SingerCFOSell6,000$28.50$171,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Reference Laboratories (NASDAQ:BRLI)
Latest Headlines for Bio-Reference Laboratories (NASDAQ:BRLI)
Source:
DateHeadline
americanbankingnews.com logoRadNet (RDNT) vs. Bio-Reference Laboratories (NASDAQ:BRLI) Head-To-Head Survey
www.americanbankingnews.com - August 9 at 4:16 PM
americanbankingnews.com logoRadNet (RDNT) vs. Bio-Reference Laboratories (NASDAQ:BRLI) Head-To-Head Comparison
www.americanbankingnews.com - August 7 at 4:28 PM
americanbankingnews.com logoFinancial Contrast: RadNet (RDNT) and Bio-Reference Laboratories (BRLI)
www.americanbankingnews.com - August 7 at 9:08 AM
americanbankingnews.com logoHead to Head Review: Bio-Reference Laboratories (NASDAQ:BRLI) vs. RadNet (RDNT)
www.americanbankingnews.com - July 30 at 7:45 AM
americanbankingnews.com logoReviewing RadNet (RDNT) & Bio-Reference Laboratories (NASDAQ:BRLI)
www.americanbankingnews.com - July 16 at 12:25 PM
americanbankingnews.com logoAnalyzing NeoGenomics (NEO) and Bio-Reference Laboratories (BRLI)
www.americanbankingnews.com - June 21 at 12:10 PM
finance.yahoo.com logoWhy Britain's NHS Is Great, Despite Its Dire Financial Situation
finance.yahoo.com - August 26 at 3:53 PM
thestreet.com logoOpko Is a Buying Opportunity After FDA's Approval of Kidney Drug
www.thestreet.com - June 30 at 5:15 PM
fool.com logoHow Risky Is Opko Health Inc. Stock?
www.fool.com - March 18 at 4:19 PM
fool.com logo3 Predictions for Opko Health Inc. in 2016
www.fool.com - December 5 at 9:03 AM
fool.com logoOpko Health Reports a Surprise Profit -- Were Investors Right to Cheer?
www.fool.com - November 19 at 7:57 AM
finance.yahoo.com logoOpko Health Has Crashed 55% In Three Months; Time To Buy?
finance.yahoo.com - September 28 at 10:44 AM
fool.com logoWhy Insiders Are Buying Opko Health, Inc. Stock
www.fool.com - September 24 at 10:24 AM
finance.yahoo.com logoOPKO HELATH, INC. Financials
finance.yahoo.com - August 25 at 1:04 PM
finance.yahoo.com logoInnospec Set to Join the S&P SmallCap 600
finance.yahoo.com - August 20 at 6:38 PM
biz.yahoo.com logoBIO REFERENCE LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisit
biz.yahoo.com - August 20 at 5:05 PM
biz.yahoo.com logoBIO REFERENCE LABORATORIES INC Files SEC form 8-K, Other Events
biz.yahoo.com - August 10 at 5:08 PM
forbes.com logoOPKO's Prostate Cancer Hit
www.forbes.com - July 23 at 8:59 AM
finance.yahoo.com logoBarron's Recap: Airline Stocks Ready To Soar
finance.yahoo.com - June 21 at 7:13 PM
finance.yahoo.com logoBRLI INVESTOR ALERT: The Law Offices of Vincent Wong Launches an Investigation of the Board of Directors of Bio-Reference Laboratories, Inc. Concerning the Sale of the Company to Opko Health Inc.
finance.yahoo.com - June 16 at 11:44 AM

Social

Chart

Bio-Reference Laboratories (BRLI) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by MarketBeat.com Staff